analysis

2:28
Midostaurin: the first drug to receive approval for AML since 2000
Arnold Ganser
1:38
Challenges with the identification of ALL subtypes
Charles Mullighan
2:24
Current understandings of ALL approaches
Charles Mullighan
1:19
Myeloma XI trial: impact of MRD on treatment response in MM
Graham Jackson
1:34
Multiple myeloma highlights at ASH 2017
Graham Jackson
2:19
ASH 2017: CLL combination therapy highlights
Arnon Kater
3:12
Results of the MURANO study for CLL
Arnon Kater
1:18
ASH 2017: combination therapy for CLL highlights
Barbara Eichhorst
1:10
Impacts of the MURANO study for future CLL treatment
Barbara Eichhorst
2:38
“Sequential triple-T” therapy for CLL
Barbara Eichhorst
2:19
Bendamustine plus rituximab vs. standard therapy for advanced CLL
Barbara Eichhorst
1:48
Novel CLL therapy highlights from ASH 2017
Anthony Mato
1:13
Checkpoint inhibitor/bispecific antibody combo: REGN2810 and REGN1979 in B-lymphoid malignancies
Anthony Mato
3:21
Triple therapy for CLL: pembrolizumab, ublituximab and umbralisib
Anthony Mato
3:36
Retrospective multicenter analysis of venetoclax-treated CLL patients
Anthony Mato
1:38
Front-line use of ibrutinib for CLL in a real-world setting
Anthony Mato
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals